Jefferies Maintains Buy on ViroPharma (VPHM)

Jefferies is out with its report today on ViroPharma VPHM, maintaining Buy. In a note to clients, Jefferies writes, "The European Medicines Agency's CHMP disclosed it gave a positive opinion to Cinryze for hereditary angioedema treatment, and we expect a decision on European approval in 2Q11. We continue to believe in the long-term potential of Cinryze as HAE prophylactic therapy." Shares of VPHM closed Friday at $19.08, up 3.58% from Thursday's close.